

Title:

Current insights on chronic intestinal dysmotility: pseudo-obstruction and enteric dysmotility

Authors:

Luis Gerardo Alcalá González, Carolina Malagelada

DOI: 10.17235/reed.2023.10038/2023

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Alcalá González Luis Gerardo, Malagelada Carolina. Current insights on chronic intestinal dysmotility: pseudo-obstruction and enteric dysmotility. Rev Esp Enferm Dig 2023. doi: 10.17235/reed.2023.10038/2023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Current insights on chronic intestinal dysmotility: pseudo-obstruction and enteric dysmotility

Luis G Alcalá-González^{1,2,3} (0000-0003-3247-1539), Carolina Malagelada^{1,2,3} (0000-0001-7097-1492)

1 Digestive System Research Unit, University Hospital Vall d'Hebron, Barcelona, Spain

2 Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Barcelona, Spain

Corresponding author: Carolina Malagelada, M.D.

Digestive System Research Unit

University Hospital Vall d'Hebron

08035-Barcelona, Spain

e-mail: carolinamalagelada@vallhebron.cat

Abstract:

Chronic intestinal dysmotility is a rare and debilitating digestive disorder characterized by symptoms of mechanical obstruction without an organic lesion. It has diverse causes and involves various pathological mechanisms. Small bowel manometry is the preferred diagnostic method, particularly for patients with severe and progressive symptoms. The condition can be categorized as intestinal pseudo-obstruction and enteric dysmotility, both entities share abnormal small bowel motility, but with important differences in prognosis and management.

The small bowel is a crucial component of the digestive system that carries out most of the digestion of ingested food. Indeed, the small bowel is the only organ of the gastrointestinal tract that human beings cannot live without. The main functions of small bowel are the efficient absorption of nutrients and the maintenance of aboral

movement of indigestible waste products. Normal small bowel motility is critical to achieve both of these important goals (1).

Clinical features and etiologies

Small bowel motility disorders are characterized by the failure of the gut to propel the luminal contents (2). Clinically, patients with chronic intestinal dysmotility present with symptoms and signs suggestive of intestinal obstruction: abdominal pain, abdominal distension and nausea with or without vomiting. During acute episodes, radiological evidence of distended bowel loops and air-fluid levels in the upright position may be seen. Acute episodes can last from a few hours to days. Between these crises, patients generally complain of severe, non-specific digestive symptoms. Constipation is usually the predominant bowel habit, but diarrhea and even steatorrhea can occur because of small bowel bacterial overgrowth (SIBO). Food ingestion often exacerbates digestive symptoms, and consequently patients tend to reduce normal oral nutrition and lose weight (3).

Chronic intestinal dysmotility may be caused by many heterogeneous conditions, primary or secondary, and can be congenital, idiopathic or acquired (Table 1) (4). Since small bowel motor activity is controlled by neuromuscular mechanisms, dysmotility can be caused by derangements of the extrinsic or intrinsic nerve pathways, the enteric plexus or the smooth muscle (5,6) (Table 1). Furthermore, more than one component can be affected at the same time in any given patient.

In the adult population, chronic intestinal dysmotility is the second most common cause of chronic intestinal failure, after short bowel syndrome, and therefore an indication for parenteral nutrition or fluid support (1). It is also an important indication for small bowel transplantation in the western world (7). Regrettably, chronic intestinal dysmotility is diagnosed late. This delay in the diagnosis can be mostly attributed to one important reason: symptoms and signs of chronic intestinal dysmotility are non-specific and the typical initial work-up including laboratory, imaging, and endoscopic studies is often unsuccessful, therefore patients are frequently misdiagnosed with a disorder of gut-brain interaction like functional dyspepsia or irritable bowel syndrome (8) (Table 2). Late diagnosis of chronic intestinal dysmotility is associated with decreased quality of life, decreased nutritional status, increased healthcare

consultation, repeated testing with negative results and unnecessary surgeries (9).

Diagnosis

The diagnosis of chronic intestinal dysmotility depends first on the exclusion of a mechanical obstruction or structural disease and second on the objective assessment of small bowel motor function by measurement of small bowel motility pressure patterns. Manometry studies measure the lumen-generated pressure inside any tubular organ and are useful to evaluate the strength, propagation, and coordination of muscle contractions, offering direct evaluation of the velocity, force, integrity and coordination of peristalsis and sphincter functions. Regrettably, manometric studies of small bowel motor function are not as commonly performed compared to manometric studies of the esophagus or the anorectum, mainly because only a few specialized centers offer the technique.

In manometry studies, the small bowel produces a series of coordinated contractions in various spatial and temporal patterns that are characteristic of fasting and fed states. During fasting, small bowel motor activity shows a repetitive cyclic motor pattern known as the migrating motor complex (MMC). The MMC is composed of three distinctive phases; Phase I is characterized by motor quiescence and succeeds phase III, phase II is characterized by irregular contractile activity, both propagated and shortly propagated, which increases in activity over time and precedes phase III; Phase III is the most easily recognizable of the MMC, is characterized by repetitive contractions at the maximal rate (10-12/min) rapidly propagating aborally. After food ingestion, small bowel motor activity changes to a postprandial pattern, characterized by an increase in irregular contractile activity and absence of the MMC phases. Postprandial motility promotes efficient digestion by mixing and propelling the luminal content in an aboral direction (Figure 1)(10).

Abnormal small bowel motility patterns detected during fasting and the fed state are used to diagnose intestinal dysmotility. Due to the significance of the diagnosis, the criteria for abnormal intestinal motility in manometry studies are very strict (11). Two studies evaluated the diagnostic yield of small bowel manometry in the real-world setting in patients with suspected chronic intestinal dysmotility. Both concluded that small bowel manometry has a high negative predictive value, and that it is most useful

ruling out intestinal dysmotility (12,13). Traditionally, abnormal small bowel motility patterns have been classified as neuropathic, myopathic and obstructive. Even though there is a poor correlation between manometric patterns and histology results, abnormal small bowel motility by manometry is associated with abnormal histology in full thickness biopsies(14). In a subset of patients, small bowel manometry will determine treatment choices and offer prognostic information. For example, small bowel manometry can be suggestive of a missed obstructive lesion and be useful to select patients for re-evaluation of organic diseases with more precise imaging or endoscopic tests(15). It can also be used to decide whether to perform a full-thickness biopsy to rule out inflammatory myoneuropathies in patients with abnormal small bowel motility by manometry, severe gastrointestinal symptoms and no evidence of the underlying cause after a thorough work-up(16).

Small bowel manometry evaluation is also susceptible to pharmacological and physiological interventions(17), and for these reason it has been used to tailor treatment with parenteral prokinetics, like octreotide or erythromycin (18). Small bowel manometry can be used to detect intestinal dysmotility in systemic disorders associated with small bowel involvement, like patients with systemic sclerosis(19) and patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)(20) even before radiological signs of pseudo-obstruction develop. Lastly, small bowel manometry also provides prognostic information, since myopathic patterns have been associated with increased mortality(21) and complete absence of fasting migrating motor complex is associated clinically with stasis of small intestinal contents, malabsorption, and SIBO(3).

Evolution and prognosis

Once the diagnosis of chronic intestinal dysmotility is established, it is imperative to search for the underlying disorder causing a neuropathy and/or myopathy (3,22) (table 1). Over the last 20 years, there has been an increasing recognition that patients with chronic intestinal dysmotility can be divided in two broad categories based on radiological findings and objective motility studies: chronic intestinal pseudo-obstruction (CIPO) and enteric dysmotility (ED)(23).

CIPO is the most severe form of chronic intestinal dysmotility, in which abnormal small intestinal motility is associated with the presence of radiological signs suggestive of intestinal obstruction but without a mechanical cause in imaging studies. Enteric dysmotility (ED) is defined by objective evidence of abnormal small bowel motility (as CIPO), but without radiological findings suggestive of intestinal obstruction (i.e. absence of intestinal dilatation or air-fluid levels).

Demographic and clinical characteristics are similar between CIPO and ED patients(24), and the objective motility abnormalities evidenced by small bowel manometry studies are the same in both entities, which suggests that CIPO and ED are closely related. Indeed, some authors advocate that ED and CIPO could be different stages of small intestinal motor disturbance. Another important similarity is that both CIPO and ED have a high incidence of neuro-muscular abnormalities in small bowel full thickness biopsies, however with some differences. CIPO patients have a higher incidence of visceral myopathies, whereas ED patients have a higher incidence of enteric neuropathies, and particularly important, a higher incidence of inflammatory neuropathies which could benefit from immunosuppressive treatment(16). There are some important differences regarding prognosis and treatment options, which validates the distinction between these two entities. CIPO patients require more intensive nutritional support compared to ED patients, and in follow-up studies, CIPO patients are less likely to wean off total parenteral nutrition(25). Still, the mortality rate is similar in both entities, therefore it is important to recognize and diagnose ED early to offer management, avoid malnutrition and improve survival.

Conclusion

In conclusion, chronic intestinal dysmotility is a rare but severely disabling gastrointestinal disorder characterized by symptoms of mechanical obstruction in the absence of an organic cause. Chronic intestinal dysmotility has multiple causes (primary, secondary, or idiopathic) and various pathological mechanisms involved (muscle, ENS, intrinsic or extrinsic pathways). Small intestinal manometry is currently the gold standard for the diagnosis and should be considered in patients with severe progressive symptoms of uncertain etiology, especially when alarm features are present to avoid delay in the diagnosis. Chronic intestinal dysmotility can be divided in

two categories, CIPO and ED, which have distinct prognostic and management considerations. Since ED without any identifiable primary or secondary cause is associated with inflammatory neuromyopathies, small bowel full thickness biopsy should be considered in the diagnostic approach.

Accepted Article

References

1. Nightingale JMD, Paine P, McLaughlin J, Emmanuel A, Martin JE, Lal S, et al. The management of adult patients with severe chronic small intestinal dysmotility. *Gut*. 2020 Dec;69(12):2074–92.
2. Gallego D, Malagelada C, Accarino A, Gori A, Malagelada JR, Azpiroz F, et al. Functional neuromuscular impairment in severe intestinal dysmotility. *Neurogastroenterol Motil*. 2018 Dec;30(12):e13458.
3. Zenzeri L, Tambucci R, Quitadamo P, Giorgio V, De Giorgio R, Di Nardo G. Update on chronic intestinal pseudo-obstruction. *Curr Opin Gastroenterol*. 2020 May;36(3):230–7.
4. Lindberg G. Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. *Best Pract Res Clin Gastroenterol*. 2019;40–41:101635.
5. Malagelada C, Malagelada JR. Small Bowel Motility. *Curr Gastroenterol Rep*. 2017 Jun;19(6):26.
6. Bianco F, Lattanzio G, Lorenzini L, Mazzoni M, Clavenzani P, Calzà L, et al. Enteric Neuromyopathies: Highlights on Genetic Mechanisms Underlying Chronic Intestinal Pseudo-Obstruction. *Biomolecules*. 2022 Dec 10;12(12):1849.
7. Clarysse M, Canovai E, Vanuytsel T, Pirenne J. Current state of adult intestinal transplantation in Europe. *Curr Opin Organ Transplant*. 2020 Apr;25(2):176–82.
8. Ghoshal UC, Bhut B, Misra A. Patients with Specific Gastrointestinal Motility Disorders are Commonly Diagnosed as Functional GI Disorders in the Early Stage by Community Physicians due to Lack of Awareness. *Turk J Gastroenterol Off J Turk Soc Gastroenterol*. 2021 Apr;32(4):336–48.
9. Vasant DH, Lal S. Recent Advances in the Management of Severe Gastrointestinal Dysmotility. *Clin Exp Gastroenterol*. 2021;14:163–72.
10. Alcalá-González LG, Malagelada C, Galan C, Nieto A, Accarino A, Azpiroz F. Propagation patterns of jejunal motor activity measured by high-resolution water-perfused manometry. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc*. 2021 Dec;33(12):e14240.
11. Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. *Gut*. 1987 Jan;28(1):5–12.

12. Verhagen MA, Samsom M, Jebbink RJ, Smout AJ. Clinical relevance of antroduodenal manometry. *Eur J Gastroenterol Hepatol*. 1999 May;11(5):523–8.
13. Ang D, Pannemans J, Vanuytsel T, Tack J. A single-center audit of the indications and clinical impact of prolonged ambulatory small intestinal manometry. *Neurogastroenterol Motil*. 2018 Sep;30(9):e13357.
14. Malagelada C, Karunaratne TB, Accarino A, Cogliandro RF, Landolfi S, Gori A, et al. Comparison between small bowel manometric patterns and full-thickness biopsy histopathology in severe intestinal dysmotility. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc*. 2018 Mar;30(3).
15. Alcalá-González LG, Malagelada C, Monrroy H, Mego M, Accarino A, Malagelada JR, et al. Clinical significance of small bowel manometry patterns suggestive of intestinal obstruction. *Neurogastroenterol Motil*. 2023 Jan;35(1):e14462.
16. Lindberg G, Törnblom H, Iwarzon M, Nyberg B, Martin JE, Veress B. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. *Gut*. 2009 Aug;58(8):1084–90.
17. Alcalá-Gonzalez LG, Malagelada C, Livovsky DM, Azpiroz F. Effect of colonic distension on small bowel motility measured by jejunal high-resolution manometry. *Neurogastroenterol Motil*. 2022 Sep;34(9):e14351.
18. Marie I, Ducrotté P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis--a prospective manometric 5-yr follow-up. *Rheumatol Oxf Engl*. 2007 Jan;46(1):150–3.
19. Marie I, Levesque H, Ducrotté P, Denis P, Benichou J, Hellot MF, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. *Arthritis Rheum*. 1998 Oct;41(10):1874–83.
20. Alcalá-González LG, Accarino A, Martí R, Sánchez-Tejerina D, Llauradó A, Azpiroz F, et al. Distinctive gastrointestinal motor dysfunction in patients with MNGIE. *Neurogastroenterol Motil*. 2023 Oct;35(10):e14643.
21. Lindberg G, Iwarzon M, Tornblom H. Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. *Scand J Gastroenterol*. 2009;44(6):692–9.

22. Gutiérrez Pérez C, Lastra Aras E, Gómez Bravo R, Chivato Martín-Falquina I, Cuenca Zarzuela A, Rodríguez Ledesma I, et al. Chronic intestinal pseudo-obstruction: diagnostic and prognostic utility of ANNA-1/Anti-Hu onconeural antibodies. *Rev Esp Enferm Dig.* 2022 Mar;114(3):175–6.
23. Wingate D, Hongo M, Kellow J, Lindberg G, Smout A. Disorders of gastrointestinal motility: towards a new classification. *J Gastroenterol Hepatol.* 2002 Feb;17 Suppl:S1-14.
24. Rosa-E-Silva L, Gerson L, Davila M, Triadafilopoulos G. Clinical, radiologic, and manometric characteristics of chronic intestinal dysmotility: the Stanford experience. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2006 Jul;4(7):866–73.
25. Vasant DH, Kalaiselvan R, Ablett J, Bond A, Abraham A, Teubner A, et al. The chronic intestinal pseudo-obstruction subtype has prognostic significance in patients with severe gastrointestinal dysmotility related intestinal failure. *Clin Nutr Edinb Scotl.* 2018 Dec;37(6 Pt A):1967–75.

Table 1: Causes of chronic intestinal dysmotility

Primary	Congenital	Visceral myopathies	<ul style="list-style-type: none"> • Multisystemic smooth muscle dysfunction syndrome (ACTA2 gene) • Visceral myopathy 1 (ACTG2 gene)
		Mitochondrial cytopathies	<ul style="list-style-type: none"> • X-linked intestinal pseudo-obstruction (L1CAM, FLNA genes) • Megacystis microcolon intestinal hypoperistalsis syndrome (MYH11, MYL9, ACTG2, MYLK genes) • Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (MT-TL1 MT-ND5 genes) • Myoclonic epilepsy with ragged red fibers (MERRF) (MTTK gene) • Mitochondrial neurogastrointestinal encephalopathy (MNGIE) (TYMP, LIG3, POLG genes)
		Visceral neuropathies	<ul style="list-style-type: none"> • Chronic atrial and intestinal dysrhythmia (SG1 gene) • Familial visceral neuropathy (ERBB3, ERBB2 genes) • Neuropathic pseudo-obstruction (SOX10 gene)
		Abnormalities in myenteric plexus development	<ul style="list-style-type: none"> • Aganglionosis • Neural dysplasia
		Mesenchymopathies	
	Idiopathic		
Secondary	Paraneoplastic	<ul style="list-style-type: none"> • Small cell lung cancer, Carcinoid, Thymoma (anti-Hu 	



Secondary

syndromes

antibodies)

Accepted Article



Secondary

Accepted Article



Paraneoplastic syndromes	<ul style="list-style-type: none">• Small cell lung cancer, Carcinoid, Thymoma (anti-Hu antibodies)	
Neurological	Central nervous involvement	<ul style="list-style-type: none">• Cerebrovascular accident, central nervous system tumors
	Medullar involvement	<ul style="list-style-type: none">• Post-trauma, vascular accidents
	Autonomic systemic dysfunction	<ul style="list-style-type: none">• Diabetes mellitus, amyloidosis, multiple system atrophy
Neuromuscular	<ul style="list-style-type: none">• Muscular dystrophy, mitochondrial cytopathy, myasthenia gravis	
Endocrine	<ul style="list-style-type: none">• Hypothyroidism, MEN2b, hyperparathyroidism, hyperthyroidism	
Post-infectious	<ul style="list-style-type: none">• Epstein-Barr virus, JC virus, Varicella-Zoster Virus, Chagas disease, Herpes simplex virus, Cytomegalovirus	
Autoimmune	Antibody mediated	<ul style="list-style-type: none">• ANNA-1 or anti Hu, anti CRMP-5/anti-CV2, anti gAChR, Guillain-Barre syndrome
	Inflammatory	<ul style="list-style-type: none">• Autoimmune myositis or ganglionitis, lymphocytic ganglionitis, eosinophilic ganglionitis
	Connective tissue diseases	<ul style="list-style-type: none">• Systemic sclerosis, mixed-connective tissue disease
	Autoimmune diseases	<ul style="list-style-type: none">• Systemic lupus erythematosus, dermatomyositis, polymyositis, Sjögren syndrome
Hereditary connective tissue disorder	<ul style="list-style-type: none">• Ehlers Danlos syndrome	
Medication related	<ul style="list-style-type: none">• Opioids and narcotics, anti-cholinergic, anti-psychotics	

	Miscellaneous	<ul style="list-style-type: none"> • Celiac disease, sarcoidosis, cystic fibrosis, intestinal ischemia, porphyria, Fabry's disease, anorexia nervosa, radiation enteritis
--	---------------	--

Table 2: Indications for manometric evaluation of small bowel motility

Patients with severe chronic digestive symptoms and signs of malnutrition in whom organic lesions have been reasonably excluded.
Patients with recurrent or sustained symptoms of intestinal sub-occlusion in whom mechanical obstruction has not been substantiated by radiological studies.
Patients with systemic disorders associated with intestinal dysmotility and severe gastrointestinal symptoms
Patients who develop chronic digestive symptoms after abdominal surgery or radiotherapy.
Patients with segmental gut motor disorders (gastroparesis, colonic inertia) to determine the extent of the disorder prior to considering respective surgery such as gastrectomy or colectomy.

Figure 1: Examples of normal and abnormal small bowel motility by high-resolution jejunal manometry. Above, in a healthy subject, a normal migrating motor complex characterized by first, a period of irregular propagated contractions (phase II), followed by a period of repetitive regular propagated contractions (phase III) and then a period of motor quiescence (phase I). Below, in a patient, abnormal configuration of phase III (simultaneous, non-propagated contractions) is observed, indicative of a neuropathic intestinal dysmotility pattern.